SCHEMBL3014372

SCHEMBL3014372

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.41
HSD11B1 P28845 1/20 0.38
ACHE P22303 2/20 0.38
BCHE P06276 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
DNM1L O00429 5/20 0.35
LMNA P02545 2/20 0.35
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017469 0.93 GBA1 (0.45) GBA1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3002256 0.92 ACHE (0.34) GBA1HSD11B1ACHESMN1; SMN2ALDH1A1
SCHEMBL3011697 0.91 HSD11B1 (0.39) GBA1HSD11B1ACHESMN1; SMN2ALDH1A1
SCHEMBL3012528 0.91 DNM1L (0.37) GBA1HSD11B1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3012703 0.91 HTR2A (0.41) GBA1HSD11B1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3015108 0.91 AOC3 (0.35) GBA1HSD11B1ACHEHRH3
SCHEMBL3014690 0.90 HSD11B1 (0.41) HSD11B1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3016045 0.90 DNM1L (0.34) GBA1HSD11B1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3017967 0.89 GBA1 (0.42) GBA1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3006460 0.89 GBA1 (0.37) GBA1SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885HSD11B1 1034/4885ACHE 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.